Namir Hassan joined Zelluna Immunotherapy in August 2018 to serve as Chief Scientific Officer. He has over 15 years of biotech and pharma industry experience spanning from target validation through to early phase clinical trials. Prior to joining Zelluna, Namir was a VP at Immunocore, responsible for creating and growing the infectious disease unit as well as helping to secure investment for the organisation. During his tenure with the company, Namir was also responsible for overseeing and strategically expanding biology, preclinical, biomarkers and development for the Oncology portfolio as well as successfully leading to completion, the first in human study treating metastatic melanoma patients.
Previously, Namir had a leadership role in the discovery research organization within GSK and has worked at the Ludwig Institute for Cancer Research. Namir received a DPhil from the University of Oxford in T-cell Biology.